The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Rapid Response Innovation Awards, 2011Identifying Approved and Investigational Drugs with Activity on Parkinson's Disease Targets
Objective:
Our objective is to identify known, safe drugs that are useful for treating Parkinson’s disease (PD). Most drugs work by interacting with specific molecular ‘targets’ in the human body, such... -
Rapid Response Innovation Awards, 2011Activation of GPR88 by a Small Molecular Weight Compound: Screening for Drug-like Modulators of GPR88 Function
Objective/Rationale:
The expression pattern of GPR88 within the brain suggests a role for this receptor in the control of motor function. The natural binding partner for GPR88 is not known. However... -
MJFF Research Grant, 2011Characterization of Inflammatory Mediators During Early Stages of Parkinson's Disease
Objective/Rationale:
Inflammatory activation has been a widely observed feature in the substantia nigra of Parkinson’s disease (PD) patients, and inflammatory stimuli can cause selective nigral cell... -
Target Validation, 2011TFEB and Its Associated MicroRNA-128 as Targets for Neuroprotection and Disease Intervention in Parkinson´s Disease
Objective/Rationale:
Recent studies indicate that degenerative changes seen in Parkinson´s disease (PD) may be linked to impairments in the cells´ ability to degrade toxic proteins, such as misfolded... -
Therapeutics Development Initiative, 2011Novel Oral Treatment for Parkinson's Disease Based on Highly Specific Modulation of the Indirect Pathway
Objective/Rationale:
Envoy Therapeutics’ target discovery technology enables the identification of new drug targets that have very selective expression in brain circuits of therapeutic interest thereby... -
Alpha-Synuclein Imaging, 2011Consortium to Develop an Alpha-synuclein Imaging Agent
Objective/Rationale:
The ultimate goal of this project is develop a positron emission tomography (PET) radiotracer to image the distribution of alpha-synuclein in the brain. Alpha-synuclein imaging...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.